Global Azacitidine Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Azacitidine Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Azacitidine Injection report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Azacitidine Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Higher-risk myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Azacitidine Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Azacitidine Injection key manufacturers include Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories, CTTQ, Huiyu Pharmaceutital and Eurohealth, etc. Celgene, Mylan, Shilpa Medicare are top 3 players and held % sales share in total in 2022.
Azacitidine Injection can be divided into 50mg and 100mg, etc. 50mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Azacitidine Injection is widely used in various fields, such as Higher-risk myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) and Others, etc. Higher-risk myelodysplastic syndromes (MDS) provides greatest supports to the Azacitidine Injection industry development. In 2022, global % sales of Azacitidine Injection went into Higher-risk myelodysplastic syndromes (MDS) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azacitidine Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

Celgene
Mylan
Shilpa Medicare
Accord Healthcare
Natco Pharma
Dr. Reddy's Laboratories
CTTQ
Huiyu Pharmaceutital
Eurohealth
Segment by Type
50mg
100mg
Higher-risk myelodysplastic syndromes (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Azacitidine Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Azacitidine Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Azacitidine Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Azacitidine Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Azacitidine Injection introduction, etc. Azacitidine Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Azacitidine Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Azacitidine Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Azacitidine Injection key manufacturers include Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories, CTTQ, Huiyu Pharmaceutital and Eurohealth, etc. Celgene, Mylan, Shilpa Medicare are top 3 players and held % sales share in total in 2022.
Azacitidine Injection can be divided into 50mg and 100mg, etc. 50mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Azacitidine Injection is widely used in various fields, such as Higher-risk myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) and Others, etc. Higher-risk myelodysplastic syndromes (MDS) provides greatest supports to the Azacitidine Injection industry development. In 2022, global % sales of Azacitidine Injection went into Higher-risk myelodysplastic syndromes (MDS) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azacitidine Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Celgene
Mylan
Shilpa Medicare
Accord Healthcare
Natco Pharma
Dr. Reddy's Laboratories
CTTQ
Huiyu Pharmaceutital
Eurohealth
Segment by Type
50mg
100mg
Segment by Application
Higher-risk myelodysplastic syndromes (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Azacitidine Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Azacitidine Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Azacitidine Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Azacitidine Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Azacitidine Injection introduction, etc. Azacitidine Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Azacitidine Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
